Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt
from central tolerance, can generate robust immune responses 1 , 2 and can function as …

Glioblastoma is the most common primary brain tumour in adults. Prognosis is poor: even
with the current gold-standard first-line treatment—maximal safe resection and combination of …

Inhibition of immune checkpoints, including cytotoxic T-lymphocyte antigen-4 (CTLA-4),
programmed death-1 (PD-1), and its ligand PD-L1, has demonstrated exciting and durable …

Purpose The prognosis for patients with recurrent glioblastoma multiforme is poor, with a
median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal …

Purpose: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements
in survival seen following currently available salvage therapy. This study was conducted to …

Background Brain metastases are a common cause of disabling neurologic complications and
death in patients with metastatic melanoma. Previous studies of nivolumab combined with …

Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …

Background Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Data from phase 2
trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in …

Purpose To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca,
Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients …

Currently, the most widely used criteria for assessing response to therapy in high-grade
gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or …